FDA approved cannabis: Why Schedule 3 means operators must prepare for pharmaceutical-grade MMJ now - MJBizDaily
FDA has rescheduled cannabis to Schedule 3, requiring operators to prepare for pharmaceutical-grade manufacturing of medical marijuana (MMJ).
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 3, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All cannabis operators and manufacturers involved in medical marijuana production. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate action required as compliance is necessary for continued operation.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Cannabis is now classified as a Schedule 3 controlled substance, necessitating compliance with pharmaceutical-grade manufacturing standards.
Who it affects
All cannabis operators and manufacturers involved in medical marijuana production.
What you must do
Begin preparations to meet cGMP requirements for pharmaceutical-grade MMJ production.
Deadline
Immediate action required as compliance is necessary for continued operation.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- DEA Announces New Marijuana Registration Forms For Manufacturing, Distribution And Testing Businesses - Marijuana Moment
- CDER’s Framework for Regulatory Advanced Manufacturing Evaluation (FRA - fda.gov
- Determination That PHENAPHEN WITH CODEINE NO. 3 (Acetaminophen; Codeine Phosphate) Oral Capsules, 325 Milligrams and 30 Milligrams, and PHENAPHEN WITH CODEINE NO. 4 (Acetaminophen; Codeine Phosphate) Oral Capsules, 325 Milligrams and 60 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Novartis, AbbVie Score Win to Block West Virginia Drug Limit Law - news.bloomberglaw.com
- FDA Tightens the Belt on GLP-1 Compounding, Escalating Threat of Enforcement - natlawreview.com